BIOMAT Database Logo BIOMAT Database Logo

Plasma angiotensin, serum 'angiotensinase activity', and blood pressure response during angiotensin II amide infusions in normal volunteers. 1971

G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey

UI MeSH Term Description Entries
D008297 Male Males
D010450 Endopeptidases A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS. Endopeptidase,Peptide Peptidohydrolases
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D012964 Sodium A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23. Sodium Ion Level,Sodium-23,Ion Level, Sodium,Level, Sodium Ion,Sodium 23
D013618 Tachyphylaxis Rapidly decreasing response to a drug or physiologically active agent after administration of a few doses. In immunology, it is the rapid immunization against the effect of toxic doses of an extract or serum by previous injection of small doses. (Dorland, 28th ed)

Related Publications

G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
The blood pressure response to infusions of angiotensin II during normal pregnancy: relation to plasma angiotensin II concentration, serum progesterone level, and mean platelet volume.
April 1992, American journal of obstetrics and gynecology,
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
Plasma angiotensinase activity on angiotensin II and analogues.
February 1967, The Australian journal of experimental biology and medical science,
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
Blood angiotensinase activity in relation to the breakdown of angiotensin II amide and nonisotopic phenylthiocarbamyl-angiotensin II amide in hypertensive and normotensive patients.
January 1968, Cardiovascular research,
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
May 1993, Hypertension (Dallas, Tex. : 1979),
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
[Relation between the blood-pressure effect of angiotensin II and the mean arterial pressure, serum sodium, serum potassium, serum angiotensinase and plasma renin in man].
May 1968, Zeitschrift fur Kreislaufforschung,
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
Plasma angiotensinase activity in relation to the breakdown of phenylthiocarbamyl-angiotensin II amide in hypertensive and normotensive patients.
January 1968, Cardiovascular research,
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
R-PEP-27, a potent renin inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers.
April 1994, American journal of hypertension,
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake.
January 1978, The Journal of clinical investigation,
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
April 1997, Journal of cardiovascular pharmacology,
G D Lubash, and G E Muiesan, and C L Alicandri, and D J Garfinkel, and E C Siekierski, and C K McConnaughey
[Renin-angiotensin system. II. Renal angiotensinase activity].
September 1969, Japanese circulation journal,
Copied contents to your clipboard!